TICKERNERD
Menu
CRSPCRSPHealthcare · Biotechnology

CRSP Stock Forecast: CRISPR Therapeutics AG Price Predictions for 2026-2027

Last close, 11 Sept 2026
$52
−1.03% on the day

The 22 Wall Street analysts covering CRISPR Therapeutics AG hold a median 12-month price target of $80 — +54.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 36 of 100 as at 12 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$5.0B
Ticker Nerd rank
36 / 100
Median analyst target
$80
Analysts covering
22
Revenue$10.0M
Operating income−$117.3M
Net income−$91.2M
Free cash flow−$86.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−8.4%
1M
−4.3%
YTD
−1.4%
1Y
−7.5%
From 52W high
−32.6%
From 52W low
+16.6%
$44
$77
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CRSP stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores CRISPR Therapeutics AG on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
36 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
78
Value
54
Growth
54
Accruals
50
Volatility
49
Quality
44
Momentum
39
Size
23
Issuance
11

Revisions (78): Analysts have, on balance, been raising their forecasts.

Issuance (11): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CRSP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CRSP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$50$100$150$200$250$300Oct 25Jan 26Apr 26Jul 26CRSPHigh $291Median $80Low $44

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says22 analysts
13 Buy9 Hold0 Sell
Low $44Median $80High $291

The green dot is the last close — the median target sits +54.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
31 Aug 2026CitizensReiteratesMarket Outperform$80
31 Aug 2026NeedhamReiteratesBuy$82
25 Aug 2026CitizensReiteratesMarket Outperform$80
4 Aug 2026CitigroupMaintainsBuy$82 → $88
4 Aug 2026CitigroupMaintainsBuy—
8 July 2026HC Wainwright & Co.ReiteratesBuy$80
8 July 2026HC Wainwright & Co.ReiteratesBuy—
6 July 2026CitizensReiteratesMarket Outperform$80
6 July 2026CitizensReiteratesMarket Outperform—
13 May 2026BernsteinMaintainsMarket Perform—
6 May 2026CitigroupMaintainsBuy—
17 Mar 2026Piper SandlerReiteratesOverweight—
17 Feb 2026Chardan CapitalMaintainsBuy—
13 Feb 2026Evercore ISI GroupMaintainsOutperform—
13 Feb 2026NeedhamMaintainsBuy—
13 Feb 2026TD CowenMaintainsHold—
30 Jan 2026CitizensMaintainsMarket Outperform—
23 Dec 2025CitizensReiteratesMarket Outperform—
23 Dec 2025NeedhamReiteratesBuy—
26 Nov 2025Chardan CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CRSP appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CRSP vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, CRISPR Therapeutics AG returned −7.5% against +17.5% for the S&P 500, dividends included.

CRSP vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120130140Oct 25Jan 26Apr 26Jul 26CRSPS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CRSP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
12
Analysts cutting
3
Fundamentals

CRISPR Therapeutics AG (CRSP) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−8.0×

Cheaper than 92% of US stocks

Price / sales
373.4×

Cheaper than 2% of US stocks

Price / book
2.9×

Cheaper than 34% of US stocks

EV / EBITDA
−6.7×

Cheaper than 81% of US stocks

Growth & margins
Revenue growth (YoY)
1041.4%

Higher than 99% of US stocks

Earnings growth (YoY)
—
Gross margin
−302.7%

Higher than 1% of US stocks

Operating margin
−1127.6%

Higher than 5% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−26.1%

Higher than 29% of US stocks

Return on assets
−14.2%

Higher than 23% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

CRISPR Therapeutics AG (CRSP) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • CRISPR Therapeutics AG has a market value of $5.0B and an enterprise value of $3.4B.

  • Revenue in the twelve months to 30 June 2026: $11.0M. The latest quarter grew 1041.4% year on year.

  • Net income over the same four quarters: −$451.1M, a −4101.3% net margin.

  • Diluted earnings per share, trailing twelve months: $−4.76.

  • Free cash flow in the twelve months to 30 June 2026: −$373.8M.

  • Shares outstanding: 96.7M.

  • Trailing P/E: −8.0×; forward P/E: −14.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • CRISPR Therapeutics AG employs 393 people — $28K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

CRSP vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CRSPCRISPR Therapeutics AG$5.0B
36
DFTXDefinium Therapeutics, Inc.$5.0B
40
ACADACADIA Pharmaceuticals, Inc.$4.8B
81
EWTXEdgewise Therapeutics, Inc.$4.8B
51
ERASErasca, Inc.$5.4B
55
PTCTPTC Therapeutics, Inc.$5.5B
65
XENEXenon Pharmaceuticals, Inc.$5.6B
50

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own CRISPR Therapeutics AG — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CRSP news & analysis

Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

The Motley Fool · 11 Sept 2026neutral

The Motley Fool published a comparison of Amgen and CRISPR Therapeutics, contrasting Amgen's stable multi-billion dollar revenue and consistent cash flows with CRISPR Therapeutics' high growth potential through pioneering gene-editing technology.

Why it matters — The piece frames CRISPR Therapeutics around its high-growth potential in gene editing, offering a data point on how the company is positioned against a large, established biopharma peer.

Axsome Therapeutics vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

The Motley Fool · 11 Sept 2026neutral

The Motley Fool published a comparison of Axsome Therapeutics and CRISPR Therapeutics as healthcare stock picks for 2026. The article notes Axsome is scaling revenue through its CNS treatment portfolio, while CRISPR is pioneering the commercial stage of gene-editing technology with its first approved therapy.

Why it matters — For CRISPR watchers, this piece highlights the company's position as a commercial-stage gene-editing pioneer drawing investor comparison and attention heading into 2026.

Why CRISPR Therapeutics Stock Rocked the Market Last Month

The Motley Fool · 8 Sept 2026positive

CRISPR Therapeutics' stock rose strongly last month after the FDA-approved drug it helped develop posted nearly an 80% sequential increase in sales. The company also recorded $10 million in upfront payments from a business partner.

Why it matters — A jump in sales of the approved therapy and new partner milestone payments signal growing commercial traction for CRISPR's pipeline.

3 Promising Genomics Stocks in the Spotlight in 2026

Zacks Investment Research · 8 Sept 2026positive

Zacks Investment Research published a piece spotlighting "3 Promising Genomics Stocks in the Spotlight in 2026," noting that genomics is reshaping healthcare and that WGS, NEO and NTLA are advancing diagnostics and precision medicine.

Why it matters — This item highlights the broader genomics sector as promising for 2026, the space in which CRISPR Therapeutics operates.

Where Will CRISPR Therapeutics Stock Be in 5 Years?

The Motley Fool · 8 Sept 2026positive

CRISPR Therapeutics is highlighted in a Motley Fool analysis examining where its stock could be in five years. The piece notes that successful pipeline development could substantially increase CRISPR's valuation, and the company has $2.36 billion to fund its expanding pipeline.

Why it matters — The article points to CRISPR's substantial cash position and the potential for pipeline successes to drive valuation gains, key factors for investors tracking the company's long-term prospects.

FAQ

Frequently asked questions about CRSP stock

What is the CRSP stock price forecast for 2026-2027?

The 22 Wall Street analysts covering CRISPR Therapeutics AG have a median 12-month price target of $80, with estimates ranging from $44 to $291. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CRSP stock a buy right now?

Of the 22 analysts covering CRISPR Therapeutics AG, 13 rate it a Buy, 9 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CRISPR Therapeutics AG 36 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CRSP?

As at 12 Sept 2026, CRISPR Therapeutics AG ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (78 of 100).

Will CRSP stock go up?

No one can know that. What the data says: the median 12-month target from 22 analysts implies +54.7% from the last close, and Ticker Nerd's factor model ranks CRISPR Therapeutics AG 36 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CRSP stock forecast for 2030?

No analyst covering CRISPR Therapeutics AG publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CRSP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $44 to $291 over the next 12 months.

How has CRSP stock performed over the past year?

CRISPR Therapeutics AG returned -7.5% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does CRISPR Therapeutics AG do?

CRISPR Therapeutics AG is a Swiss biotechnology company focused on gene editing and the development of CRISPR/Cas9-based medicines for serious human diseases. Its research and therapeutic portfolio spans areas such as hemoglobinopathies, oncology, regenerative medicine, autoimmune disorders, and type 1 diabetes.

What is the latest news on CRSP?

The most recent item we track (The Motley Fool, 11 Sept 2026): "Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?". The Motley Fool published a comparison of Amgen and CRISPR Therapeutics, contrasting Amgen's stable multi-billion dollar revenue and consistent cash flows with CRISPR Therapeutics' high growth potential through pioneering gene-editing technology.

Company

About CRISPR Therapeutics AG.

CRISPR Therapeutics AG is a Swiss biotechnology company focused on gene editing and the development of CRISPR/Cas9-based medicines for serious human diseases. Its research and therapeutic portfolio spans areas such as hemoglobinopathies, oncology, regenerative medicine, autoimmune disorders, and type 1 diabetes. The company’s work centers on using precise genome editing to create targeted cell and gene therapies, with a particular emphasis on advancing treatments derived from its proprietary CRISPR platform. CRISPR Therapeutics AG also collaborates with partners in the life sciences sector to develop and commercialize selected programs, strengthening its role in the broader healthcare innovation landscape. Headquartered in Zug, Switzerland, the company is a notable participant in the biotechnology market, where it contributes to the growing field of gene-based medicine.

CEO Dr. Samarth Kulkarni Ph.D. · 393 employees · Switzerland · https://www.crisprtx.com